All In Biotech

Drug Trial Radar · NCT03852433

Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)

A Multicenter, Open-label, Randomized Phase 2b Clinical Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Patients With Chronic Hepatitis Delta

Last checked: Nov 20, 2026Latest source record: Oct 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 175 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

175

Actual

Start

May 31, 2019

Primary completion

Apr 5, 2022

Study completion Sep 28, 2022

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Feb 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the efficacy of bulevirtide in combination with pegylated interferon in participants with chronic hepatitis delta (CHD).

Conditions

  • Chronic Hepatitis Delta

Interventions

  • BulevirtideDrug

    Administered via subcutaneous injections

  • Peginterferon Alfa-2a (PEG-IFN alfa)Drug

    Administered via subcutaneous injections

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Sustained Virological Response at Week 24 After the Scheduled End of Treatment (SVR24)Time frame: 24 weeks after EOT (Week 72 for Arm A and study Week 120 for Arms B, C, and D)

Locations

20 sites in 4 countries. Site status is shown where the registry gives one.

  • Hôpital Beaujon-Pavillon Abrami -Sce Hépatologie

    Clichy, France

  • Centre Hospitalier Universitaire Grenoble Alpes

    Grenoble, France

  • Hospital Croix Rousee

    Lyon, France

  • Hôpital Saint Joseph Hépato-Gastroentérologie

    Marseille, France

  • CH Pitié-Salpétrière - Hépato-Gastroentérologie

    Paris, France

  • Hôpital Cochin - Unité d'Hépatologie Pavillon Achard

    Paris, France

  • Infectious Clinical Hospital "T. Ciorba", Department 4 / Medical University Department of Infectious Diseases

    Chisinau, Moldova

  • Infectious Clinical Hospital "T. Ciorba", Department 5 / Medical University Department of Infectious Diseases

    Chisinau, Moldova

  • "Matei Bals" National Institute of Infectious Diseases, Hospital department

    Bucharest, Romania

  • "Matei Bals" National Institute of Infectious Diseases,Clinical Trials department

    Bucharest, Romania

  • "Victor Babes" Centre of Diagnostic and Treatment

    Bucharest, Romania

  • Dr. V. Babes Clinical Hospital of Infectious and Tropical Diseases

    Bucharest, Romania

  • State Budgetary Educational Institution of Higher Professional Education "South Ural State Medical University" of the Ministry of Healthcare of the Russian Federation

    Chelyabinsk, Russia

  • Specialized clinical Infectious diseases Hospital

    Krasnodar, Russia

  • Federal Budget Institute of Science "Central Research Institute for Epidemiology" of Federal Service on Consumers Rights Protection and Human Well-Being Surveillance

    Moscow, Russia

  • Federal State Budgetary Institution National Research Medical Center for Phthisiopulmonology and Infectious Diseases of the Ministry of Health of the Russian Federation

    Moscow, Russia

  • LLC"Clinic of Modern Medicine"

    Moscow, Russia

  • Moscow Regional Scientific and Research Clinical Institute

    Moscow, Russia

  • N.V.Sklifosovsky Scientific Research Institute of Emergency care of the Moscow Healthcare Department

    Moscow, Russia

  • LLC Medical Company "Hepatolog"

    Samara, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.